New combo therapy targets hard-to-treat neuroendocrine cancer
NCT ID NCT06132113
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 23 times
Summary
This early-phase study tests a new drug called BI 764532 added to standard chemotherapy for people with advanced neuroendocrine carcinoma (NEC). The goal is to find a safe dose and see if the combination helps shrink tumors. About 55 adults whose cancers have a specific marker (DLL3) will receive the treatment for up to 3 years if it works and is tolerable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aichi Cancer Center Hospital
RECRUITINGAichi, Nagoya, 464-8681, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cliniques Universitaires Saint-Luc
RECRUITINGBrussels, 1200, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Universitari Vall d'Hebron
RECRUITINGBarcelona, 08035, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Universitario 12 de Octubre
RECRUITINGMadrid, 28041, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Universitario La Paz
RECRUITINGMadrid, 28046, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital Louis Pradel
NOT_YET_RECRUITINGBron, 69500, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
INS Paoli-Calmettes
RECRUITINGMarseille, 13009, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
John Theurer Cancer Center
RECRUITINGHackensack, New Jersey, 07601, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Klinikum der Universität München AÖR
NOT_YET_RECRUITINGMünchen, 81377, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Cancer Center Hospital
RECRUITINGTokyo, Chuo-ku, 104-0045, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Cancer Center Hospital East
RECRUITINGChiba, Kashiwa, 277-8577, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Northwestern University
NOT_YET_RECRUITINGChicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Osaka International Cancer Institute
RECRUITINGOsaka, Osaka, 541-8567, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sahlgrenska Universitetsjukhuset
RECRUITINGGothenburg, 413 46, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Universitair Medisch Centrum Groningen
RECRUITINGGroningen, 9713 GZ, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Pittsburgh Medical Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Universitätsklinikum Tübingen
RECRUITINGTübingen, 72076, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.